糖尿病

互動

參與AIFA（Agenzia Italiana del Farmaco——義大利藥品局）的公眾諮詢、地區糖尿病工作小組，以及就獲取CGM（持續葡萄糖監測）感應器、胰島素泵及創新藥物方面作出貢獻。

互動

閱讀原文引述

我們定期倡導改善巴基斯坦全國的胰島素可及性與供應情況。2024年3月，我們舉辦了一場倡議圓桌會議，隨後與DRAP（巴基斯坦藥品監管局）進行了多次交流。

We regularly advocate for improved insulin accessibility and availability across Pakistan. In March 2024, we organized an advocacy roundtable, followed by multiple engagements with DRAP. Through these efforts, we highlighted the urgent need for the government to ensure consistent insulin access for people living with diabetes nationwide. By building strong people power and collective advocacy, we were able to drive meaningful government action. As a result, the government signed a contract for the local manufacturing of insulin, marking a major milestone in diabetes care in Pakistan. This public–private collaboration has since led to the launch of insulin products by two local pharmaceutical companies and the initiation of the Chief Minister Punjab Insulin Support Program, which is modeled after Meethi Zindagi’s Program of Insulin (POI).

行動與倡議

閱讀原文引述

與市及福利服務縣合作，將免費藥物治療延伸至2型糖尿病藥物。

Yhteydenpito kaupunkiin ja hyvinvointialueeseen maksuttoman lääkehoidon ulottamiseksi myös tyypin 2 diabeteslääkkeisiin.

行動與倡議

閱讀原文引述

將醫療器械（例如持續血糖監測儀及胰島素泵）納入全國醫療保險藥品目錄。

연속 혈당 측정기, 인슐린 펌프 등의 의료 제품의 건강 보험 등재.